CL2008000681A1 - Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona. - Google Patents

Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona.

Info

Publication number
CL2008000681A1
CL2008000681A1 CL200800681A CL2008000681A CL2008000681A1 CL 2008000681 A1 CL2008000681 A1 CL 2008000681A1 CL 200800681 A CL200800681 A CL 200800681A CL 2008000681 A CL2008000681 A CL 2008000681A CL 2008000681 A1 CL2008000681 A1 CL 2008000681A1
Authority
CL
Chile
Prior art keywords
benzoimidazol
ona
quinolin
melanoma
fluoro
Prior art date
Application number
CL200800681A
Other languages
English (en)
Spanish (es)
Inventor
Carla C Hollenbach Paul Heise
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39500684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000681(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008000681A1 publication Critical patent/CL2008000681A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200800681A 2007-03-09 2008-03-07 Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona. CL2008000681A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89404607P 2007-03-09 2007-03-09
US91140607P 2007-04-12 2007-04-12

Publications (1)

Publication Number Publication Date
CL2008000681A1 true CL2008000681A1 (es) 2008-10-24

Family

ID=39500684

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800681A CL2008000681A1 (es) 2007-03-09 2008-03-07 Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona.

Country Status (11)

Country Link
US (1) US20100086518A1 (https=)
JP (1) JP2010520881A (https=)
KR (1) KR20090119768A (https=)
AU (1) AU2008226582B2 (https=)
BR (1) BRPI0808714A2 (https=)
CA (1) CA2679268A1 (https=)
CL (1) CL2008000681A1 (https=)
MX (1) MX2009009574A (https=)
RU (1) RU2009136669A (https=)
TW (1) TW200843766A (https=)
WO (1) WO2008112509A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933702A1 (fr) * 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
TWI410418B (zh) 2009-04-29 2013-10-01 Ind Tech Res Inst 氮雜薁化合物、藥學組合物與抑制一細胞中蛋白質激酶之活性的方法
EP2432451A2 (en) * 2009-05-20 2012-03-28 Children's Medical Center Corporation Compositions for the treatment of metastatic cancer and methods of use thereof
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.
US8551479B2 (en) * 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
US10495138B2 (en) 2014-09-29 2019-12-03 Hewlett-Packard Development Company, L.P. Hinge assembly with compressible sleeve
JP6585167B2 (ja) 2014-10-03 2019-10-02 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
EP3103450A1 (en) 2015-06-12 2016-12-14 Friedrich-Alexander-Universität Erlangen-Nürnberg None-hydrophobic compounds for use in treating metastasis and/or cartilage defect
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
CN108610293B (zh) * 2018-06-15 2020-08-04 南京工业大学 一种采用微通道反应装置制备多韦替尼中间体的方法
WO2024097855A2 (en) * 2022-11-03 2024-05-10 University Of Florida Research Foundation, Incorporated Identification of small molecules that recruit and activate rnase l

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003290699B2 (en) * 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
CN102225926A (zh) * 2003-11-07 2011-10-26 诺华疫苗和诊断公司 具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
JP2009543810A (ja) * 2006-07-13 2009-12-10 ザイモジェネティクス， インコーポレイテッド インターロイキン２１およびチロシンキナーゼ阻害剤の併用治療の方法
KR20090046893A (ko) * 2006-07-28 2009-05-11 노파르티스 아게 흑색종에서 치료학적 반응에 대한 조기 지표로서의 흑색종 억제 활성 (ｍｉａ) 단백질의 용도

Also Published As

Publication number Publication date
RU2009136669A (ru) 2011-04-20
AU2008226582B2 (en) 2011-07-21
CA2679268A1 (en) 2008-09-18
JP2010520881A (ja) 2010-06-17
KR20090119768A (ko) 2009-11-19
US20100086518A1 (en) 2010-04-08
TW200843766A (en) 2008-11-16
MX2009009574A (es) 2009-09-16
WO2008112509A1 (en) 2008-09-18
AU2008226582A1 (en) 2008-09-18
BRPI0808714A2 (pt) 2014-08-12

Similar Documents

Publication Publication Date Title
CL2008000681A1 (es) Metodo de tratamiento de melanoma mediante el uso de compuestos derivados de 4-amino-5-fluoro-(benzoimidazol sustituido)-1h-quinolin-2-ona.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0815717A2 (pt) Compostos de imidazopirazina.
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK3289876T3 (da) Forbindelser til behandling af cancer
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
MA32938B1 (fr) Composes organiques
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
PL2338519T3 (pl) Środek do leczenia zwłóknienia szpiku
BRPI0811189A2 (pt) Ferramenta de nivelação composta.
IT1390737B1 (it) Macchina per la realizzazione di articoli assorbenti.
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
BRPI0912004A2 (pt) mitigação de lama.
DK2173831T3 (da) Brøndbehandling
EA201000258A1 (ru) Новые гербициды
BRPI0820440A2 (pt) Inibidores aldh-2 no tratamento de desordens psiquiátricas
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
FR2919886B1 (fr) Appareil de verrouillage de portiere.
IT1391488B1 (it) Metodo e dispositivo di spruzzatura di miscele ottenute dalla reazione di materiali polimerici.
FI20075806A0 (fi) Lukkorengas
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
BRPI0911515A2 (pt) dispositivos formadores rotatórios e métodos para o uso de tais dispositivos.